Citations

Showing 10 of 108094 citations.

Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
Korytkowski, Mary T. , Antinori-Lent, Kellie, Donihi, Amy C. , Drincic, Andjela, Luger, Anton, Nielsen, Craig , Pegg, Claire, Rushakoff, Robert J , McDonnell, Marie E , Rushakoff, Robert J , Muniyappa, Ranganath , Hirsch, Irl B. , McDonnell, Marie E. , Murad, M. Hassan , Santesso, Nancy A. , Umpierrez, Guillermo E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 12, 2022 | Volume: 107 | Issue: 8 | Pages: 2101-2128

10.1210/clinem/dgac278 | PMID 35690958 Get It

Abstract Background Adult patients with diabetes or newly recognized hyperglycemia account for over 30% of noncritically ill hospitalized patients. These patients are at increased risk for adverse clinical outcomes in the absence of defined approaches to glycemic management. Objective To review and update the 2012 Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline and to address emerging areas specific to the target population of noncritically ill hospitalized patients with diabetes or newly recognized or stress-induced hyperglycemia. Methods A multidisciplinary panel of clinician experts, together with a patient representative and experts in systematic reviews and guideline development, identified and prioritized 10 clinical questions related to inpatient management of patients with diabetes and/or hyperglycemia. The systematic reviews queried electronic databases for studies relevant to the selected questions. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make recommendations. Results The panel agreed on 10 frequently encountered areas specific to glycemic management in the hospital for which 15 recommendations were made. The guideline includes conditional recommendations for hospital use of emerging diabetes technologies including continuous glucose monitoring and insulin pump therapy; insulin regimens for prandial insulin dosing, glucocorticoid, and enteral nutrition–associated hyperglycemia; and use of noninsulin therapies. Recommendations were also made for issues relating to preoperative glycemic measures, appropriate use of correctional insulin, and diabetes self-management education in the hospital. A conditional recommendation was made against preoperative use of caloric beverages in patients with diabetes. Conclusion The recommendations are based on the consideration of important outcomes, practicality, feasibility, and patient values and preferences. These recommendations can be used to inform system improvement and clinical practice for this frequently encountered inpatient population.
Efficacy and Tolerability of Topical Platelet Exosomes for Skin Rejuvenation: Six-Week Results
Proffer, Sydney L. , Paradise, Christopher R. , DeGrazia, Emily, Halaas, Yael , Durairaj, K Kay , Somenek, Michael , Sivly, Angela , Boon, Andrea J. , Wyles, Saranya P. , Larkin, Sydney C , van Wijnen, Andre J , Behfar, Atta

Mayo Clinic

Aesthetic Surgery Journal | June 11, 2022 | Volume: 42 | Issue: 10 | Pages: 1185-1193

10.1093/asj/sjac149 | PMID 35689936 Get It

Abstract Background Exosomes are regenerative mediators for skin rejuvenation. Human platelet extract (HPE) is an allogeneic exosome product derived from US-sourced, leukocyte-reduced apheresed platelets with consistent purity and potency. Objectives The authors sought to better characterize the safety and tolerability of novel HPE (plated) Intensive Repair Serum (Rion Aesthetics, Rochester, MN) and its maximal effects on skin rejuvenation at 6 weeks. Methods This prospective, single-arm, non-randomized, longitudinal study investigated the safety and efficacy of HPE. Structured sub-analysis evaluated multifactorial improvement in skin health following standardized skin care regimen to determine the maximal effect. Evaluation at baseline and 6 weeks included participant questionnaires and photo documentation with VISIA-CR Generation 5 3D PRIMOS (Canfield Scientific Inc, Fairfield, NJ). Results VISIA-CR imaging yielded quantifiable and statistically significant improvements in overall skin health (skin health score). A greater score correlated to greater overall skin health, and there was a statistically significant mean delta improvement of 224.2 ± 112.8 (mean ± standard deviation, P ≤ 0.0001) in skin health score at 6 weeks compared with baseline. This correlated to reduction in redness, wrinkles, and melanin production across all cosmetic units (P = 0.005, P = 0.0023, P ≤ 0.0001, respectively) and significant improvements in luminosity and color evenness (P ≤ 0.001). Conclusions A topically applied platelet-derived exosome product, HPE, induced normalization to skin health at 4 to 6 weeks with improved various clinical measures of facial photodamage and cutaneous aging. It is safe, well-tolerated, and well-liked by participants. Level of Evidence: 4
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement
Come, Steven E. , Buzdar, Aman U. , Arteaga, Carlos L. , Brodie, Angela, Kristensen, Vessela N. , McDonnell, Donald P. , Osborne, C. Kent, Russo, Jose, Santen, Richard J. , Hart, Carol S. , Ingle, James N. , Colditz, Graham A. , Johnston, Stephen , Lønning, Per Eystein , Russo, José, Yee, Douglas

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 11 | Issue: 2 | Pages: 861s-864s

10.1158/1078-0432.861s.11.2 Get It

Endocrine Therapy Trials of Aromatase Inhibitors for Breast Cancer in the Adjuvant and Prevention Settings
Ingle, James N.

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 11 | Issue: 2 | Pages: 900s-905s

10.1158/1078-0432.900s.11.2 Get It

Abstract The recent past has witnessed the appearance of substantial data relating to endocrine therapy of breast cancer. In the adjuvant therapy setting in early breast cancer, several large, well-conducted, randomized, double-blind clinical trials have provided evidence for the value of the third-generation aromatase inhibitors (AI) anastrozole, exemestane, and letrozole. The three major studies to date [i.e., Arimidex, tamoxifen alone, or in combination (ATAC), International Exemestane Study (IES), and letrozole after 5 years of tamoxifen (MA.17)] evaluated three different populations of women from the standpoints of duration of prior tamoxifen and thus time since the treatment of the primary breast cancer. A consistent pattern of improvement in disease-free survival was seen whether the control arm was tamoxifen (ATAC and IES) or placebo following tamoxifen (MA.17). From a toxicity standpoint, the major findings with the AIs were a decreased incidence of thromboembolic events and endometrial cancers but an increase in musculoskeletal complaints and potential for decreasing bone density. The last issue should be clarified with ongoing studies addressing the impact of the three AIs on bone density and fractures. In summary, based on ATAC, IES, and MA.17, respectively, the following conclusions can be drawn relating to postmenopausal women with hormone receptor positive early breast cancer: anastrozole is a reasonable choice for initial endocrine adjuvant therapy, exemestane should be considered for women who have received 2 to 3 years of tamoxifen, and letrozole should be considered for those who have completed about 5 years of tamoxifen. In the prevention setting, tamoxifen has been evaluated in multiple trials involving >28,000 women and, despite clear evidence of benefit, the level of acceptance of this agent by women seems to be low. Two recently developed prevention trials, IBIS 2 and MAP.3, involve the study of aromatase inhibitors against a placebo control rather than tamoxifen. Whereas the recent adjuvant trials have established the value of the third-generation aromatase inhibitors in early-stage breast cancer, the marked reductions in contralateral breast cancers seen in these trials suggest they will be of value in the prevention setting in women at increased risk of developing the disease.
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis
Porrata, Luis F. , Litzow, Mark R. , Lacy, Martha Q. , Inwards, David J. , Ansell, Stephen M. , Micallef, Ivanna N.M., Gastineau, Dennis A., Elliott, Michele, Hayman, Suzanne R. , Tefferi, Ayalew , Gertz, Morie A. , Dispenzieri, Angela , Gastineau, Dennis A. , Hogan, William J. , Markovic, Svetomir N.

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 11 | Issue: 3 | Pages: 1210-1218

10.1158/1078-0432.1210.11.3 Get It

AbstractPurpose: Absolute lymphocyte count recovery at day 15 (ALC-15) post-autologous stem cell transplantation (ASCT) is a powerful prognostic indicator for survival for multiple hematologic malignancies and metastatic breast cancer. The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown.Experimental Design: We evaluated 145 consecutive patients with primary systemic amyloidosis who underwent ASCT at the Mayo Clinic from 1996 to 2003. The ALC-15 threshold was set at 500 cells/μL based on our previous observations.Results: The median patient follow-up was 22 months (range, 3-87 months). Higher hematologic complete response was observed in patients with an ALC-15 ≥ 500 cells/μL compared with patients with an ALC-15 < 500 cells/μL (41% versus 21%, P < 0.0008, respectively). The median overall survival and progression-free survival times were significantly better for the 59 patients that achieved an ALC-15 ≥ 500 cells/μL compared with 86 patients with ALC-15 < 500 cells/μL (not reached versus 53 months, P < 0.0003 and not reached versus 27 months, P < 0.0001, respectively). Multivariate analysis showed ALC-15 to be an independent prognostic factor for overall survival and progression-free survival.Conclusions: ALC-15 ≥ 500 cells/μL is associated with significantly improved clinical outcomes following ASCT in patients with primary systemic amyloidosis.
Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma
Burke, Louise , Flieder, Douglas B. , Guinee, Donald G., Brambilla, E., Freedman, Andrew N. , Bennett, William P., Jones, Raymond T., Borkowski, Andrew , Caporaso, Neil A., Fleming, Marian V., Trastek, Victor F., Pairolero, Peter C., Tazelaar, Henry D. , Midthun, David E. , Jett, James R., Harris, Curtis C. , Tazelaar, Henry D. , Liotta, Lance A. , Travis, William D.

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 11 | Issue: 1 | Pages: 232-241

10.1158/1078-0432.232.11.1 Get It

Abstract Purpose: Many studies have highlighted the aberrant expression and prognostic significance of individual proteins in either the Rb (particularly cyclin D1, p16INK4A, and pRb) or the p53 (p53 and p21Waf1) pathways in non–small cell lung cancer. We hypothesize that cumulative abnormalities within each and between these pathways would have significant prognostic potential regarding survival. Experimental Design: Our study population consisted of 106 consecutive surgically resected cases of predominantly early-stage non–small cell lung cancer from the National Cancer Institute-Mayo Clinic series, and assessment of proteins involved both immunohistochemical (cyclin D1, p21Waf1, pRb, p16INK4A, and p53) and mutational analysis (p53) in relationship to staging and survival. Results: Cyclin D1 overexpression was noted in 48% of the tumors, p16INK4A negative in 53%, pRb negative in 17%, p53 immunopositive in 50%, p53 mutation frequency in 48%, and p21Waf1 overexpression in 47%, none with prognostic significance. Cyclin D1 overexpression in pRb-negative tumors revealed a significantly worse prognosis with a mean survival of 2.3 years (P = 0.004). A simultaneous p53 mutation dramatically reduced the mean survival time to 0.9 years (P = 0.007). Cyclin D1 overexpression with either a p53 mutation or a p53 overexpression was also associated with a significantly poorer prognosis (P = 0.0033 and 0.0063, respectively). Conclusions: Some cumulative abnormalities in the Rb and p53 pathways (e.g., cyclin D1 overexpression and p53 mutations) significantly cooperate to predict a poor prognosis; however, the complexity of the cell cycle protein interaction in any given tumor warrants caution in interpreting survival results when specific protein abnormalities are taken in isolation.
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response
Madamsetty, Vijay Sagar , Kiers, Spencer, Alekhina, Olga, Ugolkov, Andrey , Dubé, John J. , Zhang, Yu, Zhang, Jin‐San , Wang, Enfeng , Dutta, Shamit K., Schmitt, Daniel M. , Kozikowski, Alan P. , Mazar, Andrew P. , Billadeau, Daniel D. , Alekhina, Olga , Dube, John, Zhang, Jin-San , Schmitt, Daniel M , Giles, Francis Joseph , Billadeau, Daniel D , Madamsetty, Vijay S , Ding, Li , Dube, John, Mukhopadhyay, Debabrata

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 25 | Issue: 21 | Pages: 6452-6462

10.1158/1078-0432.ccr-19-0799 | PMID 31533931 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies including PDAC. Experimental Design: Pancreatic cancer cell lines and patient-derived xenografts were treated with a novel GSK-3 inhibitor 9-ING-41 alone or in combination with chemotherapy. Activation of the DNA damage response pathway and S-phase arrest induced by gemcitabine were assessed in pancreatic tumor cells with pharmacologic inhibition or siRNA depletion of GSK-3 kinases by immunoblotting, flow cytometry, and immunofluorescence. Results: 9-ING-41 treatment significantly increased pancreatic tumor cell killing when combined with chemotherapy. Inhibition of GSK-3 by 9-ING-41 prevented gemcitabine-induced S-phase arrest suggesting an impact on the ATR-mediated DNA damage response. Both 9-ING-41 and siRNA depletion of GSK-3 kinases impaired the activation of ATR leading to the phosphorylation and activation of Chk1. Mechanistically, depletion or knockdown of GSK-3 kinases resulted in the degradation of the ATR-interacting protein TopBP1, thus limiting the activation of ATR in response to single-strand DNA damage. Conclusions: These data identify a previously unknown role for GSK-3 kinases in the regulation of the TopBP1/ATR/Chk1 DNA damage response pathway. The data also support the inclusion of patients with PDAC in clinical studies of 9-ING-41 alone and in combination with gemcitabine.
Proteomic alterations in extracellular vesicles induced by oncogenic PIK3CA mutations
Saraswat, Mayank , Garapati, Kishore , Kim, Jin Yong , Budhraja, Rohit , Pandey, Akhilesh , Budhraja, Rohit , Kim, Jinyong, Pandey, Akhilesh , Kim, Jinyong , Garapati, Kishore

Mayo Clinic

PROTEOMICS | June 11, 2022 | Volume: 22 | Issue: 19-20 | Pages: No page available

10.1002/pmic.202200077 | PMID 35689797 Get It

AbstractPIK3CA is one of the most frequently mutated genes in human cancers, with the two most prevalent activating mutations being E545K and H1047R. Although the altered intracellular signaling pathways in these cells have been described, the effect of these mutations on their extracellular vesicles (EVs) has not yet been reported. To study altered cellular physiology and intercellular communication through proteomic analysis of EVs, MCF10A cells and their isogenic mutant versions (PIK3CA E545K and H1047R) were cultured and their EVs enriched by differential ultracentrifugation. Proteins were extracted, digested with trypsin and the peptides labeled with tandem mass tag (TMT) reagents and analyzed by liquid chromatography tandem mass spectrometry (LC‐MS/MS). Four thousand six hundred and fifty‐five peptides were identified from 579 proteins of which 522 proteins have been previously described in EVs. Relative quantitation revealed altered levels of EV proteins including several cell adhesion molecules. Mesothelin, E‐cadherin, and epithelial cell adhesion molecule were elevated in both mutant cell‐derived EVs. Markers of tumor invasion and progression like galectin‐3 and transforming growth factor beta induced protein were increased in both mutants. Overall, activating mutations in PIK3CA result in altered EV composition with characteristic changes associated with these hotspot mutations.
Asplit‐face, blind, randomized placebo‐controlled clinical trial investigating the efficacy and safety of hyaluronic acid filler for the correction of atrophic facial scars
Siperstein, Robyn , Nestor, Elizabeth, Meran, Suzanne, Grunebaum, Lisa D., Grunebaum, Lisa, Nestor, Elizabeth

Mayo Clinic

Journal of Cosmetic Dermatology | June 11, 2022 | Volume: 21 | Issue: 9 | Pages: 3768-3778

10.1111/jocd.15153 | PMID 35689521 Get It

AbstractBackgroundHyaluronic acid fillers have been studied extensively for facial wrinkles; however, their efficacy for atrophic facial scars has yet to be analyzed in a prospective placebo‐controlled study.ObjectiveTo analyze the efficacy and safety of a hyaluronic acid filler for atrophic facial scars.Methods & MaterialsFifteen subjects were randomized to receive up to 1 ml of VYC‐17.5 L on one cheek and up to 1 ml of saline on the other side, with an optional touch‐up treatment. Subjects were graded by a live blind evaluator using the Quantitative Global Scarring Grading System (QGSGS) (J Cosmet Dermatol. 2006;5:48), the Global Aesthetic Improvement Scale (GAIS), and Canfield photo‐analysis.ResultsAccording to the blind evaluator, there was a significant reduction 90 days after the last treatment on the QGSGS for VYC‐17.5L compared with saline (−6.6 VYC‐17.5L vs −1.7 saline [t(28) = −4.3196,p = 0.008]). There was a smaller, but still significant reduction on the QGSGS for saline alone (10.4 to 8.6 [t(14) = −3.453,p = 0.004]). In addition, 93% (13/14) of subjects chose VYC‐17.5L over saline treatment and reported an improvement on the GAIS. There were no serious side effects and all minor side effects resolved by Day 30.ConclusionVYC‐17.5L achieved significant improvements in rolling atrophic scars as compared to saline, though saline also had modest improvements.
Linaclotide utilization and potential for off-label use and misuse in three European countries
Ruzafa, Javier Cid , Lacy, Brian E. , Schultze, Anna , Lu, Yi , Raluy-Callado, Mireia , Donaldson, Robert M. , Weissman, Darren, Gómez-Lumbreras, Ainhoa , Ouchi, Dan , Giner‐Soriano, Maria , Ukah, Ahunna, Pohl, Daniel , Cid-Ruzafa, Javier , Duong, Mai, Donaldson, Robert, Morros, Rosa

Mayo Clinic

Therapeutic Advances in Gastroenterology | June 11, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221100946 | PMID 35706826 Get It

Introduction: Linaclotide is approved for adults with moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C). Linaclotide is not indicated for weight loss or for patients with inflammatory bowel disease (IBD); it is contraindicated in patients with mechanical bowel obstruction (MBO). Some patients with obesity or eating disorders (ED) may use linaclotide off-label for weight loss or as a laxative. Objectives: To describe the use of linaclotide in clinical practice, including patients with potential for off-label use or misuse. Methods: Post-authorization safety study conducted in three databases from the linaclotide launch date to 2017: the Clinical Practice Research Datalink in the United Kingdom (UK), the Information System for Research in Primary Care database in Spain and the linked Patient, Prescription and Causes of Death Registries in Sweden. Cohorts of patients were identified as having IBS using diagnostic and treatment codes; IBS subtypes were identified using symptoms and treatment codes; patients with obesity, ED, MBO, and IBD were identified using diagnostic codes or body mass index. Results: There were 1319, 1981, and 5081 linaclotide users from the United Kingdom, Spain, and Sweden with a median age of 45, 57, and 51 years, respectively; most were females. In the United Kingdom, Spain, and Sweden, respectively: 59.0%, 60.3%, and 31.3% of linaclotide users had an IBS diagnosis recorded, and among those, 68.8%, 61.3%, and 92.7% were classified as IBS-C. The proportions of linaclotide users considered at risk for potential off-label use for weight loss or as a laxative were 17.1%, 29.7%, and 1.7%, and the proportions of users considered at risk of misuse due to a history of MBO or IBD were 3.5%, 4.6%, and 5.7% in the United Kingdom, Spain, and Sweden, respectively. Conclusions: Potential linaclotide off-label use and misuse appears limited, as evidenced by the small sizes of the patient subgroups at risk for off-label use and misuse.